ATE253914T1 - Farnesyl protein transferase inhibitoren zur behandlung von arthropathien - Google Patents

Farnesyl protein transferase inhibitoren zur behandlung von arthropathien

Info

Publication number
ATE253914T1
ATE253914T1 AT99931230T AT99931230T ATE253914T1 AT E253914 T1 ATE253914 T1 AT E253914T1 AT 99931230 T AT99931230 T AT 99931230T AT 99931230 T AT99931230 T AT 99931230T AT E253914 T1 ATE253914 T1 AT E253914T1
Authority
AT
Austria
Prior art keywords
arthropathies
treatment
protein transferase
transferase inhibitors
farnesyl protein
Prior art date
Application number
AT99931230T
Other languages
English (en)
Inventor
David William Janssen Rese End
Roads
Marina Lucie Louise Cools
Wauwe Jean Pierre Frans Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE253914T1 publication Critical patent/ATE253914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT99931230T 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitoren zur behandlung von arthropathien ATE253914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202258 1998-07-06
PCT/EP1999/004546 WO2000001386A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors for treating arthropathies

Publications (1)

Publication Number Publication Date
ATE253914T1 true ATE253914T1 (de) 2003-11-15

Family

ID=8233891

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931230T ATE253914T1 (de) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitoren zur behandlung von arthropathien

Country Status (34)

Country Link
US (1) US6451812B1 (de)
EP (1) EP1094815B1 (de)
JP (1) JP4491136B2 (de)
KR (1) KR100674122B1 (de)
CN (1) CN1170538C (de)
AP (1) AP1597A (de)
AT (1) ATE253914T1 (de)
AU (1) AU762470B2 (de)
BG (1) BG64939B1 (de)
BR (1) BR9911869A (de)
CA (1) CA2337800C (de)
CZ (1) CZ302269B6 (de)
DE (1) DE69912790T2 (de)
DK (1) DK1094815T3 (de)
EA (1) EA003510B1 (de)
EE (1) EE04579B1 (de)
ES (1) ES2212580T3 (de)
HK (1) HK1034450A1 (de)
HR (1) HRP20000904A2 (de)
HU (1) HU229358B1 (de)
ID (1) ID27199A (de)
IL (2) IL140720A0 (de)
MY (1) MY122189A (de)
NO (1) NO318338B1 (de)
NZ (1) NZ509647A (de)
PL (1) PL193296B1 (de)
PT (1) PT1094815E (de)
SI (1) SI1094815T1 (de)
SK (1) SK285231B6 (de)
TR (1) TR200003882T2 (de)
TW (1) TW557212B (de)
UA (1) UA64797C2 (de)
WO (1) WO2000001386A1 (de)
ZA (1) ZA200100152B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64797C2 (uk) 1998-07-06 2004-03-15 Янссен Фармацевтика Н.В. Інгібітори фарнезил білок трансферази як засіб для лікування артропатії
EP1106612B1 (de) * 1999-11-30 2004-02-11 Pfizer Products Inc. Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322644A1 (de) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. 6-heterocyclylmethyl chinolon derivate und deren verwendung als farnesyl transferase inhibitoren
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1322636A1 (de) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. 6-(substituierte phenyl)methyl)chinolin- und chinazolinderivate und deren verwendung als farneyl transferase inhibitoren
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
US7129356B2 (en) 2000-12-27 2006-10-31 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US6706699B2 (en) * 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
EP1691812A4 (de) 2003-11-20 2010-01-13 Childrens Hosp Medical Center Gtpase-hemmer und anwendungsverfahren
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ME01509B (me) 2004-11-05 2014-04-20 Janssen Pharmaceutica Nv Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
BRPI0811781A2 (pt) * 2007-05-23 2014-11-11 Allergan Inc Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
NZ593090A (en) 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
ES2673847T3 (es) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anticuerpos anti KIT y usos de los mismos
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
US9309222B2 (en) * 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
SI2909192T1 (sl) * 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
CN112695039A (zh) 2013-08-26 2021-04-23 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
EP3057950B1 (de) * 2013-10-15 2020-12-02 Janssen Pharmaceutica NV Phenylgebundene chinolinylmodulatoren von ror-gamma-t
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
US9284308B2 (en) * 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) * 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2863074T3 (es) 2014-06-04 2021-10-08 Biontech Res And Development Inc Anticuerpos monoclonales humanos contra el gangliósido GD2
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
JP6630742B2 (ja) 2015-08-17 2020-01-15 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
CA3006769A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
EP3824287A1 (de) 2018-07-20 2021-05-26 Pierre Fabre Médicament Rezeptor für vista

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
CA2251716A1 (en) 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
AU709409B2 (en) * 1996-07-15 1999-08-26 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
WO1998049157A1 (en) 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
CN1231215C (zh) 1997-06-02 2005-12-14 詹森药业有限公司 (咪唑－5－基)甲基－2－喹啉酮衍生物用作平滑肌细胞增殖抑制剂
PE83799A1 (es) 1997-06-17 1999-10-23 Schering Corp Compuestos para la inhibicion de la farnesilo transferasa
EA003877B1 (ru) 1998-07-06 2003-10-30 Янссен Фармацевтика Н.В. Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
UA64797C2 (uk) 1998-07-06 2004-03-15 Янссен Фармацевтика Н.В. Інгібітори фарнезил білок трансферази як засіб для лікування артропатії
ID27562A (id) * 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
JP5574025B1 (ja) * 2013-06-25 2014-08-20 大日本印刷株式会社 飲料供給系配管の殺菌方法及び装置

Also Published As

Publication number Publication date
EE200000770A (et) 2002-04-15
PL345352A1 (en) 2001-12-17
BR9911869A (pt) 2001-03-27
EA003510B1 (ru) 2003-06-26
AU4780699A (en) 2000-01-24
CA2337800C (en) 2007-12-04
DK1094815T3 (da) 2004-03-29
TW557212B (en) 2003-10-11
PT1094815E (pt) 2004-04-30
HRP20000904A2 (en) 2001-12-31
CZ302269B6 (cs) 2011-01-19
IL140720A0 (en) 2002-02-10
NO318338B1 (no) 2005-03-07
HK1034450A1 (en) 2001-10-26
ID27199A (id) 2001-03-08
EE04579B1 (et) 2006-02-15
DE69912790T2 (de) 2004-09-23
SI1094815T1 (en) 2004-04-30
DE69912790D1 (de) 2003-12-18
SK19872000A3 (sk) 2001-08-06
CN1308535A (zh) 2001-08-15
CA2337800A1 (en) 2000-01-13
CN1170538C (zh) 2004-10-13
WO2000001386A1 (en) 2000-01-13
EP1094815A1 (de) 2001-05-02
EA200100112A1 (ru) 2001-06-25
MY122189A (en) 2006-03-31
ES2212580T3 (es) 2004-07-16
EP1094815B1 (de) 2003-11-12
TR200003882T2 (tr) 2001-06-21
NZ509647A (en) 2003-12-19
JP2002519379A (ja) 2002-07-02
KR20010052771A (ko) 2001-06-25
NO20010053D0 (no) 2001-01-04
KR100674122B1 (ko) 2007-01-26
AU762470B2 (en) 2003-06-26
JP4491136B2 (ja) 2010-06-30
IL140720A (en) 2008-08-07
HUP0103670A3 (en) 2003-01-28
CZ20004778A3 (en) 2001-05-16
SK285231B6 (sk) 2006-09-07
BG64939B1 (bg) 2006-10-31
ZA200100152B (en) 2002-01-07
BG105110A (en) 2001-11-30
NO20010053L (no) 2001-03-02
PL193296B1 (pl) 2007-01-31
AP1597A (en) 2006-04-26
HUP0103670A2 (hu) 2002-02-28
UA64797C2 (uk) 2004-03-15
AP2001002058A0 (en) 2001-03-31
HU229358B1 (en) 2013-11-28
US6451812B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
ATE253914T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE69806579D1 (de) Anlage zur behandlung von nahrungsmitteln
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1094815

Country of ref document: EP